ICP-105 is a highly selective FGFR4 inhibitor developed for HCC with abnormal FGFR4 signaling. In cell and animal models, ICP-105 selectively inhibits proliferation of tumor cell with activated FGFR4, and demonstrate strong anti-tumor activity in HCC Xenografts.ICP-105 has excellent drug like properties such as solubility, permeability and bioavailability.
• Hepatocellular carcinoma (HCC) is one of the most challenging solid tumor world wide. There are 710,000 new HCC cases every year, and most of them with poor prognosis due to advanced stage and lack of effective therapies. The average five-year survival rate for all liver cancer cases in developing countries is only about 5%, therefore there is a high unmet need for drugs with good efficacy and safety. ICP-105 offers a novel mechanism for treatment of HCC.